- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17:26 | BMS expands AI footprint with Nvidia, aiming for 'most powerful AI factory in life sciences' | ||
| 16:26 | Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds | ||
| 16:26 | Kolon's cell-based gene therapy fails phase 3 osteoarthritis trial | ||
| Fr | BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields | ||
| Fr | Jasper Therapeutics finds new purpose in merger with Kira Pharmaceuticals, while offloading Tavneos rival to Mirador | ||
| Fr | 5 emerging biotech hubs | ||
| Fr | GSK axes key cough drug candidate after phase 3 data end blockbuster hopes | ||
| Fr | Dimerix snaps up Mission's stalled, phase 2-ready kidney disease candidate in $292M deal | ||
| Do | Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trial | ||
| Do | Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health market | ||
| Do | Vogenx joins the IPO queue to fund phase 2-stage metabolic drug | ||
| Mi | Braveheart aims for freedom with IPO to support Hengrui-licensed cardio asset | ||
| Mi | Big Pharma-backed AdvanCell, flush with $315M series D, ready to put radiotherapy pedal to the metal | ||
| Mi | J&J axes eye disease gene therapy after key phase 2b readout | ||
| Mi | AAIC: Roche 'very interested' in testing tau for Alzheimer's despite focus on phase 3-stage amyloid drug | ||
| Mi | Attovia files for IPO to take on Sanofi and Regeneron's Dupixent | ||
| Di | FDA plans to release more drug rejection letters as controversial policy resumes | ||
| Di | Biogen defends anti-tau drug after stock slides on Alzheimer's readout | ||
| Di | Chai brews up $400M series C to fuel AI molecule models used by Lilly, Novartis and Pfizer | ||
| Di | Summit sells failed antibiotic to OpenAI-backed startup in $105M deal | ||
| Di | Avere goes public via NextCure reverse merger, secures Hansoh IL-23 drug with $2.3B deal | ||
| 13.07. | Merck KGaA institutes in-office requirement for US research team that could lead to 70 layoffs | ||
| 13.07. | FDA releases 14 new drug rejection letters after 3-month pause in transparency policy | ||
| 13.07. | Q32's stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors | ||
| 13.07. | Agenus scraps phase 3 colorectal study after 3 months to narrow focus to colon cancer |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.